Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Antimicrob Chemother ; 76(10): 2702-2707, 2021 09 15.
Article in English | MEDLINE | ID: mdl-34278431

ABSTRACT

BACKGROUND: Mycoplasma genitalium is an emergent cause of sexually transmitted disease (STD). The first-line treatment is azithromycin, but macrolide resistance is increasing due to mutations in the 23S rRNA gene. OBJECTIVES: To determine the rates of M. genitalium infection and macrolide resistance in an area adjacent to Barcelona. METHODS: This 1 year prospective study was performed in a heterogenous population that included both low- and high-risk patients. M. genitalium was detected in all specimens sent to our institution for STD detection. Epidemiological and relevant clinical data were collected in the positive cases. Characterization of macrolide-associated resistance was performed by 23S rDNA sequencing. RESULTS: Of the 3540 patients included, 132 (3.7%) were positive for M. genitalium. Another sexually transmitted bacteria was detected in 20.4% of the M. genitalium cases, and Chlamydia trachomatis (11%) was the most frequently co-detected microorganism. Only 61.4% of patients received an adequate initial treatment against M. genitalium. The test of cure (TOC) was performed in 42% of patients, and therapeutic failure was detected in 10 cases. The rate of macrolide resistance was 12.6% and the most prevalent mutation was A2058G. There was an association between macrolide resistance and a previous history of M. genitalium detection (P < 0.001). CONCLUSIONS: Our results support the contribution of the previous use of macrolides in resistant strains. Given the difficulties in performing TOC in all patients, the inclusion of macrolide resistance in the detection test should be mandatory.


Subject(s)
Mycoplasma Infections , Mycoplasma genitalium , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial , Humans , Macrolides/pharmacology , Mycoplasma Infections/drug therapy , Mycoplasma Infections/epidemiology , Mycoplasma genitalium/genetics , Prospective Studies , Spain/epidemiology
2.
Article in English | MEDLINE | ID: mdl-30323038

ABSTRACT

Although the Sensititre Yeast-One (SYO) and Etest methods are widely utilized, interpretive criteria are not available for triazole susceptibility testing of Candida or Aspergillus species. We collected fluconazole, itraconazole, posaconazole, and voriconazole SYO and Etest MICs from 39 laboratories representing all continents for (method/agent-dependent) 11,171 Candida albicans, 215 C. dubliniensis, 4,418 C. glabrata species complex, 157 C.guilliermondii (Meyerozyma guilliermondii), 676 C. krusei (Pichia kudriavzevii), 298 C.lusitaniae (Clavispora lusitaniae), 911 C.parapsilosissensu stricto, 3,691 C.parapsilosis species complex, 36 C.metapsilosis, 110 C.orthopsilosis, 1,854 C.tropicalis, 244 Saccharomyces cerevisiae, 1,409 Aspergillus fumigatus, 389 A.flavus, 130 A.nidulans, 233 A.niger, and 302 A.terreus complex isolates. SYO/Etest MICs for 282 confirmed non-wild-type (non-WT) isolates were included: ERG11 (C. albicans), ERG11 and MRR1 (C. parapsilosis), cyp51A (A. fumigatus), and CDR2 and CDR1 overexpression (C. albicans and C. glabrata, respectively). Interlaboratory modal agreement was superior by SYO for yeast species and by the Etest for Aspergillus spp. Distributions fulfilling CLSI criteria for epidemiological cutoff value (ECV) definition were pooled, and we proposed SYO ECVs for S. cerevisiae and 9 yeast and 3 Aspergillus species and Etest ECVs for 5 yeast and 4 Aspergillus species. The posaconazole SYO ECV of 0.06 µg/ml for C. albicans and the Etest itraconazole ECV of 2 µg/ml for A. fumigatus were the best predictors of non-WT isolates. These findings support the need for method-dependent ECVs, as, overall, the SYO appears to perform better for susceptibility testing of yeast species and the Etest appears to perform better for susceptibility testing of Aspergillus spp. Further evaluations should be conducted with more Candida mutants.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus/drug effects , Candida/drug effects , Triazoles/pharmacology , Aspergillosis/drug therapy , Aspergillosis/epidemiology , Aspergillosis/microbiology , Aspergillus/classification , Aspergillus/isolation & purification , Candida/classification , Candida/isolation & purification , Candidiasis/drug therapy , Candidiasis/epidemiology , Candidiasis/microbiology , Disk Diffusion Antimicrobial Tests , Drug Resistance, Fungal , Fluconazole/pharmacology , Humans , Immunocompromised Host , Itraconazole/pharmacology , Voriconazole/pharmacology
3.
Clin Microbiol Infect ; 23(10): 776.e1-776.e5, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28412383

ABSTRACT

OBJECTIVES: A prospective international multicentre surveillance study was conducted to investigate the prevalence and amphotericin B susceptibility of Aspergillus terreus species complex infections. METHODS: A total of 370 cases from 21 countries were evaluated. RESULTS: The overall prevalence of A. terreus species complex among the investigated patients with mould-positive cultures was 5.2% (370/7116). Amphotericin B MICs ranged from 0.125 to 32 mg/L, (median 8 mg/L). CONCLUSIONS: Aspergillus terreus species complex infections cause a wide spectrum of aspergillosis and the majority of cryptic species display high amphotericin B MICs.


Subject(s)
Aspergillosis/epidemiology , Aspergillosis/microbiology , Aspergillus/classification , Aspergillus/isolation & purification , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Aspergillus/drug effects , Epidemiological Monitoring , Europe/epidemiology , Humans , Microbial Sensitivity Tests , Prevalence , Prospective Studies
4.
Antimicrob Agents Chemother ; 59(11): 6725-32, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26282428

ABSTRACT

Neither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established for Candida spp. with anidulafungin, caspofungin, and micafungin when using the Sensititre YeastOne (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable. Candida species wild-type (WT) MIC distributions (for microorganisms in a species/drug combination with no detectable phenotypic resistance) were established for 6,007 Candida albicans, 186 C. dubliniensis, 3,188 C. glabrata complex, 119 C. guilliermondii, 493 C. krusei, 205 C. lusitaniae, 3,136 C. parapsilosis complex, and 1,016 C. tropicalis isolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO ECVs. ECVs for anidulafungin, caspofungin, and micafungin encompassing ≥97.5% of the statistically modeled population were, respectively, 0.12, 0.25, and 0.06 µg/ml for C. albicans, 0.12, 0.25, and 0.03 µg/ml for C. glabrata complex, 4, 2, and 4 µg/ml for C. parapsilosis complex, 0.5, 0.25, and 0.06 µg/ml for C. tropicalis, 0.25, 1, and 0.25 µg/ml for C. krusei, 0.25, 1, and 0.12 µg/ml for C. lusitaniae, 4, 2, and 2 µg/ml for C. guilliermondii, and 0.25, 0.25, and 0.12 µg/ml for C. dubliniensis. Species-specific SYO ECVs for anidulafungin, caspofungin, and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81 Candida isolates with identified fks mutations. SYO ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin, and especially caspofungin, since testing the susceptibilities of Candida spp. to caspofungin by reference methodologies is not recommended.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Echinocandins/pharmacology , Lipopeptides/pharmacology , Anidulafungin , Candida/genetics , Caspofungin , Micafungin , Microbial Sensitivity Tests , Mutation/genetics
5.
Antimicrob Agents Chemother ; 59(6): 3570-3, 2015.
Article in English | MEDLINE | ID: mdl-25779577

ABSTRACT

We evaluated FKS1 and FKS2 mutations in Candida parapsilosis bloodstream isolates and correlated them with the echinocandin MIC values determined by guidelines in CLSI document M27-A3 and the YeastOne panel. All mutations detected were outside hot spot (HS) regions. The F1386S mutation detected in an isolate that was resistant by the YeastOne panel but not by the M27-A3 guidelines might be implicated in echinocandin resistance. Further studies are needed to confirm the implication of the F1386S mutation and to elucidate the capability of the M27-A3 guidelines to detect echinocandin resistance.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Echinocandins/pharmacology , Candida/genetics , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Mutation
6.
Rev. clín. esp. (Ed. impr.) ; 213(7): e63-e66, oct. 2013.
Article in Spanish | IBECS | ID: ibc-115618

ABSTRACT

Presentamos el caso de un paciente con fiebre, síndrome tóxico y lesiones pulmonares cavitadas. La positividad de la serología de VIH, la ausencia de mejoría con tratamiento tuberculostático, y el trabajo conjunto de clínicos, microbiólogos y patólogos permitió llegar al diagnóstico de infección por Penicillium marneffei. Además, el caso refuerza la importancia de una correcta evaluación de los antecedentes epidemiológicos (AU)


A 33-year-old Spanish man presented with fever, expectoration, weight loss and lung cavitary lesions. HIV-positive serology, the lack of clinical improvement under anti-tuberculosis treatment, and the teamwork carried by clinicians, microbiologists and pathologists led to the diagnosis of Penicillium marneffei infection. This case supports the importance of the correct evaluation of the epidemiological history of the patients (AU)


Subject(s)
Humans , Male , Adult , Penicillium , Penicillium/isolation & purification , Penicillium/pathogenicity , HIV/isolation & purification , HIV/pathogenicity , Mycoses/complications , Mycoses/diagnosis , Opportunistic Infections/complications , Opportunistic Infections/diagnosis , Fever/complications , Opportunistic Infections/physiopathology , Opportunistic Infections/therapy , Fever/etiology , AIDS-Related Opportunistic Infections/complications , Antitubercular Agents/therapeutic use
7.
Nutr Hosp ; 11(2): 141-7, 1996.
Article in Spanish | MEDLINE | ID: mdl-8695711

ABSTRACT

When faced with the frequent use of parenteral nutrition (TPN) and the multiple problems which the maintenance of venous pathways presents, we initiated this study to try and show that the use of TPN catheters for the perfusion of drugs in "Y", does ot increase the incidence of infection. 70 patients subjected to TPN were studied, divided into 3 groups: I: TPN with exclusive use catheter (23 patients). II: TPN with a catheter through which antibiotic medication is administered in "Y" (22 patients). III: TPN with a catheter through which non-antibiotic medication is administered in "Y" (25 patients). Despite there being no extra manipulation in group I, when applying Cramer's "Y" we did not find any significant differences between the three groups as to incidence of infection. When relating the variables of infection and number of manipulations by means of chi-squared, we did not find significant differences either. There is no increase in the incidence of infection with the increase of manipulation. When we relate the variables of infection and number of days of treatment with TPN by chi-squared, we did not find significant differences either. There were no more infections of the catheters with more days of treatment. Neither did we find significant differences with respect to the number of manipulations, according to the calculation done by the Student T-rest, between groups II and III. Therefore, we have reached the conclusion that although the use of TPN for the administration of other drugs should not be used indiscriminately, it is absolutely valid for concrete cases, with a difficulty of multiple venolysis, as long as the drugs that shall be administered are stable with TPN and as a long as the norms form the correct administration and the aseptic techniques are observed.


Subject(s)
Cross Infection/etiology , Equipment Contamination , Parenteral Nutrition, Total/adverse effects , Pharmaceutical Preparations/administration & dosage , Bacteremia/epidemiology , Bacteremia/etiology , Catheterization, Central Venous/adverse effects , Catheterization, Central Venous/instrumentation , Catheterization, Central Venous/methods , Catheterization, Central Venous/statistics & numerical data , Chi-Square Distribution , Cross Infection/epidemiology , Equipment Contamination/statistics & numerical data , Humans , Incidence , Parenteral Nutrition, Total/instrumentation , Parenteral Nutrition, Total/methods , Parenteral Nutrition, Total/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...